NCT04344795 - Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 6, 2020

Primary Completion Date

September 25, 2024

Study Completion Date

September 25, 2024

Conditions

Solid TumorColorectal CancerNon Small Cell Lung CancerSquamous Cell Carcinoma of Head and NeckUrothelial CarcinomaEndometrial CancerGastroesophageal Junction AdenocarcinomaGastric AdenocarcinomaSolid Tumors With PIK3Ca Mutation

Interventions

DRUG

TPST-1495 twice daily

TPST-1495 administered orally twice daily

DRUG

TPST-1495 once daily or on intermittent schedule

TPST-1495 administered orally once daily or on intermittent schedule

DRUG

Pembrolizumab

Pembrolizumab dosed per label recommendations

Trial Locations (11)

15213

University of Pittsburgh Medical Center, Pittsburgh

19104

University of Pennsylvania Perelman School of Medicine, Philadelphia

21287

Sidney Kimmel Cancer Center, Johns Hopkins School of Medicine, Baltimore

28078

Carolina BioOncology Institute, Huntersville

37203

Tennessee Oncology, Nashville

48109

University of Michigan Rogel Cancer Center, Ann Arbor

49546

START Midwest, Grand Rapids

73104

SCRI-OK Stephenson Cancer Center, Oklahoma City

78229

South Texas Accelerated Research Therapeutics (START), San Antonio

80045

University of Colorado, Aurora

01107

Baystate Gynecologic Oncology, Springfield